EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Clyde Launches New Contractility Service – CellOPTIQ®-X
Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma
Enterprise Therapeutics Appoints Dr. John Ford as CEO
Brighton, UK, October 17, 2016 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment
EM Imaging Win Best Emerging Medtech Company Award
Edinburgh, Scotland, October 7, 2016 – At the OBN Awards 2016 dinner in Oxford last night, Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company
Apellis Pharmaceuticals Announces Appointment of Dr. Robert Kim as Chief Medical Officer
LOUISVILLE, Ky., Aug. 8, 2016 – Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the expansion of its executive team with the addition of Dr.
Epidarex Capital Creates Nodthera Limited
A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland, July 28, 2016: Epidarex Capital today announces the
Mind the Gap – Sinclair Dunlop on Venture Capital and the Funding Gap in Scotland
Business Quarter interviews Sinclair Dunlop, Managing Partner of Epidarex Capital on venture capital, innovation, and the funding gap in Scotland. Click here for a link
Apellis Announces Positive Results from Phase 1 Clinical Trials of APL-2, a C3 Complement Inhibitor
LOUISVILLE, Ky., June 23, 2016 – Apellis Pharmaceuticals, Inc. today announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2.
Mironid Announces Closing of £4.3 million Series A Financing
Glasgow, Scotland, UK, 20th June 2016: Mironid Ltd, a leader in cell signalling directed drug development, today announced the closing of its Series A funding